News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
OptiNose AS Announces Publication of Positive Subgroup Analysis Evaluating Efficacy of Fluticasone Delivered with Novel Drug Delivery Technology
August 10, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
YARDLEY, Pa.--(BUSINESS WIRE)--OptiNose Inc. announced today that a subgroup analysis of positive Phase II trial results has been published in the July/August issue of the American Journal of Rhinology & Allergy.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
MORE ON THIS TOPIC
Obesity
Skye’s CB1 Inhibitor Shows ‘Intriguing Synergy’ With Wegovy, Despite Mid-Stage Obesity Fail
October 7, 2025
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Amgen Builds Case for Repatha To Prevent Heart Disease With Late-Stage Data
October 3, 2025
·
1 min read
·
Tristan Manalac
IN PARTNERSHIP WITH PII
Hit Me With Your Best Shot: Understanding Autoinjectors and Combination Drug Delivery Systems
October 2, 2025
·
1 min read
·
BioSpace Insights
Podcast
M&A Picks Up, Walmsley Moves On, Pfizer’s MFN Deal and Hope for Huntington’s
October 1, 2025
·
2 min read
·
Heather McKenzie
